Related stories
Precision Biosciences Reports Third-Quarter 2026 Results
Revenue was $0 versus $13K a year earlier. Net loss narrowed to $7.6M from $21.8M, including a $12.7M non-cash gain from changes in warrant fair value. Diluted EPS was $(0.28), com
M impact | EQUITY | Nov 03, 2026, 01:19 PM UTC
JBT Marel Q3 Adjusted Earnings Rise as Revenue Falls; 2026 EPS Guidance Lifted
JBT Marel reported higher adjusted earnings and lower revenue for Q3, and lifted its 2026 adjusted EPS guidance.
M impact | EQUITY | Nov 03, 2026, 01:11 PM UTC
Clarivate Reports Third-Quarter Revenue of $481.6 Million and Net Loss
Third-quarter 2026 revenue fell 9.2% to $481.6 million from $530.3 million a year earlier. Net loss was $80.8 million, or $0.13 per diluted share, versus a $28.3 million net loss a
M impact | EQUITY | Nov 03, 2026, 01:11 PM UTC
Faeth Therapeutics Reports Third-Quarter Net Loss of $20.4 Million
Faeth reported a $20.4 million net loss for the third quarter of 2026, compared with a $4.6 million loss a year earlier. Basic and diluted loss per share narrowed to $0.79 from $3.
M impact | EQUITY | Nov 03, 2026, 01:11 PM UTC
Dynatrace Reports Fiscal Q2 Revenue of $579.92 Million, EPS of $0.23
Revenue rose 17.4% year over year to $579.92 million. Net income increased 18.4% to $67.76 million, and diluted EPS rose 21.1% to $0.23.
M impact | EQUITY | Nov 03, 2026, 01:11 PM UTC
Sysco Names Brandon Sewell Chief Financial Officer
Sysco named Brandon Sewell its chief financial officer.
L impact | EQUITY | Nov 03, 2026, 01:11 PM UTC